Collaborative multicenter efforts will be required to further extend patient numbers even in rare disorders like MPN, to specifically explore the effect of anti-PF4/heparin IgG for overt thrombosis in PV and ET. This evidence concerns the gene PF4 and myeloproliferative disorder.